Penumbra Inc — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Penumbra reported Q2 2026 revenue of $390.0M (+14.9% YoY), with thrombectomy revenue at $259.0M (+12.5%) and embolization/access at $131.1M (+20.0%). Gross margin expanded to 67.9% (+1.9pp). Net income was $34.8M in Q2 2026 vs. $45.3M in Q2 2025; the company incurred $6.9M in acquisition-related expenses. The pending acquisition by Boston Scientific (NYSE: BSX) is ongoing, and Penumbra will not provide full-year 2026 guidance or host a conference call.
Why this rating
Solid organic growth (14.9% revenue) and margin expansion are routine business performance. Pending acquisition dominates narrative but is already known. $6.9M transaction costs immaterial to $9.7B market cap (0.07%). Guidance withdrawal reflects acquisition uncertainty, not business deterioration. No new material developments.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.